hcc whiteboard #3: the management of adverse events of tyrosine kinase inhibitors
Published 6 years ago • 2.3K plays • Length 3:12Download video MP4
Download video MP3
Similar videos
-
4:58
hcc whiteboard #2: the mechanisms of action of tyrosine kinase inhibitors
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
19:09
harnessing the kinome: multi-kinase inhibitors for the management of hepatocellular carcinoma
-
1:13:43
highlights from bruton’s tyrosine kinase inhibitors
-
13:51
how to integrate new agents in hcc: the role of tkis
-
27:26
tyrosin kinase inhibitor 2
-
4:50
h3c ad-campus solution
-
15:34
"tips and tricks for dlc in complex cto cases" - dr. mashayekhi - dlc masterclass @ euroctoclub 2021
-
23:37
kinase inhibitors and immunomodulatory drugs - what does the future hold for lymphomas?
-
3:58
csf1 inhibition in tsgct: managing adverse events
-
15:57
part 2 investigator insights: emerging multikinase inhibitors in the treatment of thyroid cancers
-
55:23
hepatocellular carcinoma: a guide to integrating emerging therapies into current treatment paradigms
-
6:45
anti-pd1 or tyrosine kinase inhibitors?
-
7:45
the feasibility of tki discontinuation
-
20:24
targeted treatment with egfr tkis: front line options
-
3:12
second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
-
2:31
discontinuation of second generation tyrosine kinase inhibitors
-
3:15
tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
-
2:03
dr. george on dosing tkis in rcc
-
6:08
measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia
-
1:27
dr. grigg on frontline tyrosine kinase inhibitors in rcc
-
16:15
nsclc: targeting rtks